Provectus Biopharmaceuticals Inc (QB) (PVCT) News

The part of this that gives me some optimism is that the Bascom Palmer institute is a recognized leader in eye care. Unlikely they would hitch their wagon to something that did not have merit. I look forward to seeing the outcome of this collaboration.

NEWS -- Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology

KNOXVILLE, Tenn., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today the launch of VisiRose, Inc. (“VisiRose”), Provectus’s first Founded Entity. This new clinical-stage biotechnology company is focused on commercializing Rose Bengal Photodynamic Antimicrobial Therapy (“RB PDAT”) for the treatment of infectious keratitis and other serious eye infections using Provectus’s bioactive synthetic small molecule and active pharmaceutical ingredient (“API”) Rose Bengal Sodium (RBS). The University of Miami (the “University”) is a minority equity shareholder of VisiRose.

RB PDAT, a groundbreaking, non-invasive investigational treatment for eye infections, is based on innovative ocular research from the Ophthalmic Biophysics Center at Bascom Palmer Eye Institute (“BPEI”) of the University’s Miller School of Medicine. RB PDAT combines a formulation of Provectus’s pharmaceutical-grade RBS API and OBC’s light-based medical device to treat eye infections caused by bacteria, fungi, and parasites, including multidrug-resistant organisms.

Dominic Rodrigues, Acting Chief Executive Officer of VisiRose, who is also President and Vice Chairman of the Board of Directors of Provectus, said, “RB PDAT represents a consequential solution for patients at risk of vision loss from infectious keratitis. We believe this innovative therapy combines precise infection-fighting capabilities with vision-preserving benefits, paving the way for a brighter future for those struggling with this challenging condition.”

Ed Pershing, Chairman of the Boards of Directors of VisiRose and Provectus added, “VisiRose exemplifies Provectus’s forward-thinking business model, bridging innovation and impact. Spinning off this clinical-stage, ophthalmology-focused entity enhances our ability to address unmet medical needs while unlocking value for our stockholders. By focusing on a high-growth area like eye care, we are both advancing RB PDAT and maximizing the intrinsic value of RBS and, ultimately, Provectus’s market position.”

A copy of VisiRose’s press release from December 10, 2024 of its launch may be found here: https://www.accesswire.com/952319/visirose-introduces-revolutionary-therapy-for-severe-eye-infections.

VisiRose’s website is accessible here: https://visirose.com/.

About VisiRose

VisiRose is a newly launched clinical-stage biotechnology company of the University of Miami and Provectus Biopharmaceuticals, focused on commercializing the Miller School of Medicine’s Bascom Palmer Eye Institute and its Ophthalmic Biophysics Center’s innovative ocular research using Provectus’s bioactive synthetic small molecule Rose Bengal Sodium (“RBS”). For more information, please visit https://visirose.com.

About Bascom Palmer Eye Institute

Bascom Palmer Eye Institute serves as the Department of Ophthalmology for the University of Miami Miller School of Medicine. The mission of BPEI is to enhance the quality of life by improving sight, preventing blindness, and advancing ophthalmic knowledge through compassionate patient care and innovative research. For 2024-2025, U.S. News & World Report (“U.S. News”) ranked BPEI as the nation’s best in ophthalmology, marking the 23rd time and 21st consecutive year that BPEI has received the No. 1 ranking since U.S. News began surveying American physicians for its annual “Best Hospitals” rankings 35 years ago.

About Provectus

Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of bioactive synthetic small molecules called halogenated xanthenes. The Company’s lead molecule is RBS. Provectus’s small molecule drug platform includes:

Clinical development programs in oncology, dermatology, and ophthalmology,

In vivo proof-of-concept programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers, and

In vitro discovery programs in infectious diseases, tissue regeneration and repair, and several proprietary targets.Information about the Company’s clinical trials can be found at the National Institutes of Health registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at https://www.provectusbio.com.

Forward Looking Statements

The information in this press release may include “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.

Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.

Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including those described in Item 1A of Provectus’s:

Annual Report on Form 10-K for the period ended December 31, 2023, and

Quarterly Report on Form 10-Q for the period ended September 30, 2024.Contacts:

Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
mailto://hraines@pvct.com
(866) 594-5999

VisiRose, Inc.
Dominic Rodrigues
Acting Chief Executive Officer
mailto://rodrigues@visirose.com
(866) 216-7333

Investor Relations & Media
Provectus: Alliance Advisors Investor Relations
Alyssa Barry
mailto://alyssa@irlabs.ca
(833) 947-5227

NEWS -- VisiRose Introduces Revolutionary Therapy for Severe Eye Infections

Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals

KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites.

RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular therapy that may be safe, effective, and cost-efficient. The treatment has shown rapid infection resolution and improved patient outcomes in clinical trials across the U.S., India, Brazil, and Mexico.

"RB PDAT is a revolutionary, non-invasive treatment showing remarkable promise for patients with severe infectious keratitis. This innovative therapy harnesses the power of light to combat infection and offers new hope for preserving vision," said Jean-Marie Parel, IngETS-G, Ph.D., FAIMBE, FARVO, Director and co-founder of the Ophthalmic Biophysics Center at BPEI.

Guillermo Amescua, M.D., Professor of Clinical Ophthalmology, Medical Director of the Ocular Microbiology Laboratory, and a board-certified ophthalmologist at BPEI added, "VisiRose is crucial for translating the innovation of RB PDAT from the laboratory to a widely accessible treatment, ultimately benefiting countless patients worldwide."

"VisiRose is the bridge that connects innovation with impact. It enables us to bring the hope of RB PDAT to patients who desperately need it, transforming lives and shaping the future of eye care," said Ed Pershing, Chairman of the Board of Directors of VisiRose and Provectus.

Dominic Rodrigues, Acting CEO of VisiRose added, "RB PDAT offers a beacon of hope for patients facing the threat of vision loss from infectious keratitis. This innovative therapy, with its targeted action and dual benefits, represents a significant advancement in eye care, paving the way for a brighter future for those struggling with this challenging condition."

In more than 500 patients, RB PDAT has shown promising results in treating severe eye infections where traditional therapies have failed. VisiRose is poised to address a significant gap in the $60 billion global ophthalmic market, focusing on regions and populations impacted by rising AMR and the lack of access to effective treatments.

About VisiRose

VisiRose is a newly launched, clinical-stage biotechnology company of the University of Miami and Provectus Biopharmaceuticals, focused on commercializing the Miller School of Medicine's Bascom Palmer Eye Institute and its Ophthalmic Biophysics Center's innovative ocular research using Provectus's bioactive synthetic small molecule Rose Bengal Sodium (RBS). For more information, please visit: https://visirose.com.

About Bascom Palmer Eye Institute

The Bascom Palmer Eye Institute, part of the University of Miami Health System, is consistently ranked #1 in ophthalmology in the U.S. by U.S. News & World Report. Known for its cutting-edge research and clinical excellence, Bascom Palmer provides world-class care across all ophthalmic subspecialties and is at the forefront of developing innovative treatments for eye diseases. With a commitment to advancing both patient care and medical research, it is recognized globally as a leader in ophthalmology. For more information, please visit: https://umiamihealth.org/en/bascom-palmer-eye-institute.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals (OTCQB: PVCT) is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of bioactive synthetic small molecules called halogenated xanthenes. The Company's lead molecule is named Rose Bengal Sodium.

Provectus's drug platform includes:

Clinical development programs in oncology, dermatology, and ophthalmology,

In vivo proof-of-concept programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers, and

In vitro discovery programs in infectious diseases, tissue regeneration and repair, and several proprietary targets.Information about the Company's clinical trials can be found at the National Institutes of Health (NIH) registry, https://www.clinicaltrials.gov. For more information, please visit: https://www.provectusbio.com.

For Media Inquiries:
VisiRose, Inc.
E: mailto://contact@visirose.com
W: https://visirose.com

Contact:
VisiRose, Inc.
Dominic Rodrigues
Acting Chief Executive Officer
E: mailto://rodrigues@visirose.com

SOURCE: VisiRose

View the original press release on accesswire.com

So previous attempts at treating infectious keratitis using steroids and topical solutions have not netted favorable results. UV light and riboflavin actually worsened pain, increased corneal scarring, and had no impact on microbiologic cure rate per the article. If Provectus pulls this off in the NIH REAGIR study, it would be huge for the company and patient population. I did not realize that the wait on "Eye Company" news was due to readouts of this trial, thought the clinical demonstration of proof of treatment was already concluded. Was hoping we had an operational company and revenue stream in 2025, looks like that may be optimistic.

"All Eyes on Bascom Palmer"

Substack Link Here

"So, in regards to Provectus and its prospective clinical-stage ophthalmology start-up spinout, “EyeCo,” the ophthalmology community awaits the results of the NIH NEI-funded REAGIR study, a double-masked, sham-controlled trial of RB PDT for the treatment of fungal and acanthameoba keratitis7. REAGIR is the acronum for the Rose Bengal Electromagnetic Activation with Green Light for Infection Reduction (REAGIR) study (NCT05110001)."

NEWS -- Provectus Biopharmaceuticals Announces Investor Webinar for Fourth Quarter 2024 Conference Call

KNOXVILLE, Tenn., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its Fourth Quarter 2024 Investor Update will be accessible by Zoom Webinar. The conference call will be held on Thursday, November 14, 2024 starting at 2 p.m. EST.

The Fourth Quarter 2024 Investor Update webinar may be accessed by registering in advance here:

https://us06web.zoom.us/webinar/register/WN_u628Om3GTyCrclcuZckXNg?_ga=2.250060678.1412167732.1728519054-492896892.1650903731#/registration.

About Provectus

Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of bioactive synthetic small molecules called halogenated xanthenes. The Company’s lead molecule is named Rose Bengal Sodium. Provectus’s small molecule drug platform includes:

Clinical development programs in oncology, dermatology, and ophthalmology,In vivo proof-of-concept programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers, andIn vitro discovery programs in infectious diseases, tissue regeneration and repair, and several proprietary targets.Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at https://www.provectusbio.com.

Forward-Looking Statements

The information in this press release may include “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.

Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.

Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including those described in Item 1A of Provectus’s:

Annual Report on Form 10-K for the period ended December 31, 2023, and

Quarterly Report on Form 10-Q for the period ended June 30, 2024.

Contacts:

Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
mailto://hraines@pvct.com
(866) 594-5999

Investor Relations & Media
IR Labs Inc. (irlabs) (now Alliance Advisors Investor Relations)
Alyssa Barry
mailto://alyssa@irlabs.ca
(833) 947-5227

NEWS -- Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call

KNOXVILLE, Tenn., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that it will host a conference call on Thursday, November 14, 2024 starting at 2 p.m. EST to provide Company updates.

Conference call details will be provided closer to the date of the event.

About Provectus

Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of bioactive synthetic small molecules called halogenated xanthenes. The Company’s lead molecule is named Rose Bengal Sodium. Provectus’s small molecule drug platform includes:

Clinical development programs in oncology, dermatology, and ophthalmologyIn vivo proof-of-concept programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers, andIn vitro discovery programs in infectious diseases, tissue regeneration and repair, and several proprietary targets.Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at https://www.provectusbio.com.

Forward Looking Statements

The information in this press release may include “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.

Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.

Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including those described in Item 1A of Provectus’s:

Annual Report on Form 10-K for the period ended December 31, 2023, andQuarterly Report on Form 10-Q for the period ended June 30, 2024.Contacts:

Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
mailto://hraines@pvct.com
(866) 594-5999

Investor Relations & Media
IR Labs Inc. (irlabs)
Alyssa Barry
mailto://alyssa@irlabs.ca
(833) 947-5227

so, any thoughts on the Summit Therapeutics drug trial results? Showing better results than Keytruda? Maybe an opportunity to use PV-10 to help boost Keytruda results when used in combo?

Are they good?

Phase 1 results.

From today’s PR

Third Quarter 2024 Conference Call Plans (September)

Provectus plans to hold a third quarter 2024 conference call, with a Q&A portion, by or before the end of September.

Excellent review! I was disappointed on the timelines, but I think solid progress is being made. I was at the meeting and I think you’re right. The meeting was well received although there is frustration that we’re not moving quicker.

Any thoughts on the annual meeting would be appreciated; including posts from the other boards.

I listened online and thought the overall presentation portion after the formal meeting was good, both Ed and Dom are certainly unique and highly competent investor/officers of the company. Dominic stated the number #1 priority of the company remains the pancreatic/uveal focus though all other clinical applications from other areas were a close number #2; said the company was able to work on multiple fronts without losing sight of overall goal. Wanted the company to clearly become the "expert" resource of all PV10 matters/requests/inquiries. Said progress delay in prior years actually proved to be well spent time as mechanics and capabilities of the molecule are now so much better understood. He was hesitant to give future dates on when initial patients will be dosed in the upcoming trial as he did not want to set false expectations. Made several statements or comments on the need for speed but must be tempered since making uniformed decisions would likely lead to poor outcomes from rushing ahead; something the company can ill afford. Sounds to me they are hearing the shareholders request for progress loud and clear, and have Dominic's support and understanding, but hurdles and unforeseen obstacles are nonetheless in place that make forecasting end dates irresponsible.

Both Dominic and Ed were disappointed about the lack of funding options/pharmaceutical interest available to them at this time, would consider international funding if the right option presented itself. A remark from the audience afterwards even questioned how serious Big Pharma investment would even be for backing a disease "cure" as they were so dependent on selling their maintenance cocktails. Ed believes differently and stated there are good people at these companies and that hopefully the new focus on communications will have a positive impact. Both mentioned a responsibility to the long supporting shareholders so dilution from second tier financing resources fortunately does not seem to a concern. As many of long time shareholders have heard in the past, funding continues to be an ongoing issue. The reverse split is available if needed or would be helpful for the long term growth of the company. They want it as an option on hand but do not have specific plans when/if to use it; NASDAQ listing could eventually be a reason but they are a ways off from accomplishing that.

The Eye company comments were interesting, even though it seems like we are a ways away from having a company established. Awaiting on outcome results from India even though the rose bengal being used is not pharmaceutical grade from PVCT. Then the cost of starting the company will need to be determined. Getting FDA approval for the new company will actually benefit PVCT as the FDA also focuses on clinical grade and the manufacturing environment for approval, and we have the patents in place for our benefit. Additional comments were made on wound healing, canine cancer, anti-infection properties and other such opportunities; all in various stages of initial development.

Dominic listed a multitude of successful achievements in the prior year but it went by to quickly, I will have to view them once posted.

Though I thought the meeting was well received, I can see how some long term shareholders would get frustrated as this was all a bit generic and no time frames were committed to. At the same time, Ed and Dom said they could not be more optimistic, sounds like the industry is starting to take some notice as well. There is no doubt of Ed & Dom's commitment to this company. I will be holding and adding on larger dips in the upcoming year, I think the potential of the molecule warrants that. Hopefully a revenue stream can be forecast at next year's meeting, the company desperately needs an ongoing cash inflow. I remain optimistic but will be back in 'wait and see' mode.

NEWS -- Provectus Biopharmaceuticals Announces Investor Webinar for 2024 Annual Meeting of Stockholders

KNOXVILLE, Tenn., June 13, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its 2024 annual stockholder meeting (the “2024 Annual Meeting”), including meeting activities and a company update, will be accessible by Zoom Webinar. The meeting will be held on Thursday, June 20, 2024 at the Hilton Knoxville, located at 501 West Church Avenue, Knoxville, Tenn., beginning at 4:00 p.m. Eastern Time.

The 2024 Annual Meeting webinar may be accessed by registering in advance here:
https://us06web.zoom.us/webinar/register/WN_KZTlQulrRCOZ2qQI4C23mQ#/registration.

The webinar is being made available only for informational purposes. The 2024 Annual Meeting is being held in person, and accessing the webinar will neither count as attendance for purposes of meeting quorum requirements nor enable a stockholder to vote. Provectus’s stockholders of record at the close of business on April 24, 2024, the record date for the 2024 Annual Meeting, may vote at the meeting by attending in person or following the instructions in the Company’s proxy materials.

Availability of Proxy Materials

In connection with the 2024 Annual Meeting, Provectus has filed a definitive proxy statement with the Securities and Exchange Commission (the “SEC”) on May 6, 2024, which may be found here:
https://www.sec.gov/Archives/edgar/data/315545/000149315224017882/formdef14a.htm.

The Company mailed a Notice of Internet Availability of Proxy Materials (“Notice”) to its stockholders on or about May 10, 2024. These materials, along with Provectus’s 2023 Annual Report, are available on the Company’s website and may be found here: https://www.provectusbio.com/annual-meeting/.

About Provectus

Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic bioactive small molecules called halogenated xanthenes. The Company’s lead HX molecule is named Rose Bengal Sodium.

Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.

Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at https://www.provectusbio.com.

Forward Looking Statements

The information in this press release may include “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.

Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.

Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the SEC, including those described in Item 1A of:

The Annual Report on Form 10-K for the period ended December 31, 2023, and

The Quarterly Report on Form 10-Q for the period ended March 31, 2024.

Additional Information and Where to Find It

This communication may be deemed to be solicitation material in connection with the proposals to be submitted to the Company’s stockholders at its 2024 Annual Meeting. STOCKHOLDERS ARE URGED TO READ CAREFULLY AND, IN ITS ENTIRETY, THE DEFINITIVE PROXY STATEMENT FILED WITH THE SEC AND OTHER RELEVANT MATERIALS, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE 2024 ANNUAL MEETING PROPOSALS. A Notice with instructions for accessing the definitive proxy statement, 2023 Annual Report, and proxy card was mailed on or about May 10, 2024 to stockholders as of the record date of April 24, 2024. Stockholders may obtain free copies of Provectus’s definitive proxy statement and its other SEC filings electronically by accessing the SEC’s home page at http://www.sec.gov. Copies can also be obtained, free of charge, upon written request to Provectus Biopharmaceuticals, Inc., Attn: Secretary, 800 S. Gay Street, Suite 1610, Knoxville, Tennessee 37929, (866) 594-5999. Copies can also be obtained electronically from the Company’s Annual Meeting webpage, https://www.provectusbio.com/annual-meeting/.

Participants in Solicitation

The Company and its directors, executive officers, and advisors may be deemed to be participants in the solicitation of proxies from the holders of Provectus’s Common Stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock in respect of the 2024 Annual Meeting proposals.

Investors may obtain additional information regarding the interest of those participants by reading the Company’s definitive proxy statement and other relevant proxy materials, and Provectus’s annual reports on Form 10-K and quarterly reports on Form 10-Q, as filed with the SEC.

Contacts:

Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
(866) 594-5999

Investor Relations & Media
IR Labs Inc. (irlabs)
Alyssa Barry
mailto://alyssa@irlabs.ca
(833) 947-5227

thx Trimble ... I've not yet re-joined IVillage.

here's a post I put up a few hours ago on the IVillage PVCT semi-private and Group Boards, reconstituted here if you don't have access to those boards:

Block trading today
Interesting consecutive block trading this morning between 9:52:11 and 9:53:16 ET, 245,000 then 250,000 then 476,923 then 143,100 then 250,000 shares traded, all at $.19, a total of 1,365,023 shares out of a day total of 1,883,184 shares traded. That left 518,161 shares traded the rest of the day, which would be a fairly heavy day of trading for PVCT outside of the fact that there were 66,000 shares traded pre-market at $.165, $.1711 and $.1721, and then 105,000 shares traded within 1 second after the opening at $.165 and then another 80,000 shares traded at 9:48:22 at $.1899. Throw in a 50,000 share trade at 10:32:16 for $$.196 and then 2 31,322 share trades at $.1901 and $.1902, and you have a grand total of 1,598,667 shares block traded out of that total of 1,883,184 total shares traded.

That left 284,517 shares traded in smaller lots, a more usual pattern for PVCT.

Is someone saying something to us, with this unusual activity?

It happened early today, so somebody definitely took a position.

Interesting pop on volume today. Maybe somebody out there likes what they see. Only $342k transacted or so, but a bit more than lunch money.

Down 3 cents earlier this morning on no news. Just wanted to check in again before lunch, and it is back to almost flat. I understand the need for the MM to have some latitude on price, to make a market, but this is getting ridiculous. Take the price higher for a change.

totally agree... the minute there is some monetization of PV 10 , this stock will be a gold mine

Interesting approach for directed radiation. I like your thought about a possible application for PV-10. Hopefully a clinician can weigh in on the merits. PV-10 seeking out solid tumors throughout the body seems like a potential candidate if it can somehow carry the targeting particle.

Looking forward to the start of an ocular revenue stream next year. This company finally starting to inch forward. Great potential.

take a look at this article - https://www.cnbc.com/2024/05/23/this-up-and-coming-cancer-treatment-could-be-a-25-billion-market-opportunity.html Tell me PV-10 isnt in this potential category?

NEWS -- Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting

Accelerates wound closure and improves wound healing
KNOXVILLE, TN, May 21, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that non-clinical data on Provectus’s proprietary, pharmaceutical-grade, rose bengal sodium (“RBS”) active pharmaceutical ingredient for the topical treatment of full-thickness cutaneous wounds were presented at the annual meeting of the Society for Investigative Dermatology (“SID”), held May 15-18, 2024 in Dallas, Texas.

This work is part of research being conducted by Amina El Ayadi, PhD, Assistant Professor, Surgical Sciences Division of the Burn, Trauma, and Critical Care Research Laboratory in the Department of Surgery at the University of Texas Medical Branch at Galveston (“UTMB”).

A copy of UTMB’s poster presentation is available here: https://www.provectusbio.com/media/docs/publications/SID-2024_Poster-PV-10-2-42x44_inches-El_Ayadi.pdf.

The UTMB team and Dr. El Ayadi concluded that:

The application of multidose 0.01% RBS every other day under ambient light (“RBS treatment”) to full-thickness wounds showed:No toxicity or mortality,No loss in body weight,No organ abnormalities, andNo observed adverse effect level at the highest tested dose,
Transepidermal water loss was significantly reduced by 14 days, suggesting improvement in skin barrier function,Erythema was increased at seven days, suggesting increased blood flow and granulation tissue formation required for wound healing,Vascularity was increased between three and seven days, supporting pro-angiogenic activity needed for wound closure,RBS treatment:

Accelerated wound closure (significant difference at three days),Increased collagen density at seven and 14 days, supporting increased wound remodeling and tissue regeneration, andReduced angiogenesis after wound closure (day 14), which is beneficial in preventing fibrosis.About University of Texas Medical Branch at Galveston

Starting from the Texas City Disaster of 1947, the deadliest industrial accident in U.S. history and one of history’s largest non-nuclear explosions, UTMB clinicians and researchers in the Department of Surgery have developed treatments that improve the survival chances of patients with massive burns, reduce scar formation, and accelerate patient recovery. Many novel treatments discovered by UTMB researchers have been adopted by specialist burn centers around the world. The Department of Surgery’s Burn, Trauma, and Critical Care Research Laboratory is equipped with an array of cutting-edge equipment and technologies that support its research activities, including a dedicated cell culture suite, confocal microscope, flow cytometer, Comprehensive Lab Animal Monitoring System, and bioprinter for 3D cell culture.

About Provectus

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus’s lead HX molecule is named rose bengal sodium.

Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.

Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at https://www.provectusbio.com.

FORWARD-LOOKING STATEMENTS: The information provided in this press release may include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Such statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.

The safety and efficacy of Provectus’s drug agents and/or their uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any revenue levels.

Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and the Company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.

Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission, including those described in Item 1A of the Company’s:

Annual Report on Form 10-K for the period ended December 31, 2023, and

Quarterly Report on Form 10-Q for the period ended March 31, 2024.

#####

Contact:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999

Ed on TV

https://x.com/provectusbio/status/1791979755556012512?s=42&t=eoWvSfGJtbPqpIx0qp7yWw

From Provectus's most recent substack posting.



this seems so astonishing to me ... we've just got to find a way to get this to the people it can benefit.

Full substack post here.

Can’t seem to break past that .20 point.

NEWS -- Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting

PDAT clinical outcomes for infectious keratitis from Brazil and Mexico

KNOXVILLE, TN, May 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that clinical and non-clinical data on rose bengal photodynamic antimicrobial therapy (“RB PDAT”) were presented at the annual meeting of the Association for Research in Vision and Ophthalmology (“ARVO”), held May 5-9, 2024 in Seattle, Washington. The ARVO annual meeting brings together approximately 10,000 vision researchers, clinicians, and scientists from around the world for scientific sessions, poster presentations, and invited speaker sessions.

Provectus entered into an exclusive worldwide license agreement with the University of Miami (the “University”) in April 2024 for its intellectual property related to RB PDAT for treating bacterial, fungal, and parasitic (acanthamoeba) eye infections. The Company and University plan to form a start-up biotechnology company (e.g., “Eyecare NewCo”), potentially in the third quarter of 2024, aimed at commercializing the University’s PDAT light source medical device in combination with a drug formulation of Provectus’s proprietary pharmaceutical-grade rose bengal active pharmaceutical ingredient (“RB API”). The Company would contribute the RB PDAT license to and have an exclusive RB API supply arrangement with Eyecare NewCo.

RB PDAT emerged under the leadership of Jean-Marie Parel, IngETS-G, Ph.D., FARVO, Director of Bascom Palmer Eye Institute’s (“BPEI’s”) Ophthalmic Biophysics Center at the University of Miami Miller School of Medicine. Dr. Parel and the OBC team have spent more than ten years advancing RB PDAT technology against different types of infectious keratitis.

ARVO 2024 RB PDAT presentations included:

Evaluating the Safety of Rose Bengal Photodynamic Therapy, Huang et al., BPEI (Poster no. B0448, Session: Cornea),

Rose Bengal Photodynamic Antimicrobial Therapy as an Adjuvant Treatment for Infectious Keratitis, Eskenazi-Betech et al., Instituto de Oftalmologia Fundacion Conde de Valenciana IAP (Mexico) (B0338, Cornea),

Assessment of photosensitizer concentration with a Singlet Oxygen luminescence dosimeter for Photodynamic Antimicrobial Therapy, Carrera et al., BPEI (B0570, Cornea),

Clinical outcome in patients with infectious keratitis treated with Rose Bengal Photodynamic Antimicrobial Therapy (RB-PDAT) at the Federal University of Sao Paulo (UNIFESP), Tabuse et al., Universidade Federal de São Paulo (Brazil) (B0575, Cornea),

Enhanced Fungal Inhibition with High-Dose Rose Bengal Photodynamic Antimiocrobial Therapy, Merikansky et al., BPEI (B0580, Cornea),

Inhibition of Fungal Isolates via Singlet Oxygen Generation from Erythrosin B and Rose Bengal Photodynamic Antimicrobial Therapy, Ahmed et al., BPEI (Paper no. 4917, Cornea),

Arginine-Mediated Enhancement of Photodynamic Antimicrobial Therapy to Target the Oxygen-Independent Pathway, Gonzalez et al., BPEI (B0005, Immunology/Microbiology), and

Preclinical/Poster: Exploring the Combination of Rose Bengal Photodynamic Antimicrobial Therapy and Existing Antifungals, Krishna et al., BPEI (B0010, Immunology/Microbiology).RB PDAT is the subject of two international Phase 3 randomized controlled trials for acanthamoeba and fungal (NCT05110001) and bacterial (NCT06271772) keratitis, and has been used to treat infectious keratitis patients in four countries to date:

U.S.: BPEI (first clinical reporting: Naranjo et al. 2019),India: LV Prasad Eye Institute (Bagga et al. 2022) and Aravind Eye Care System (NCT05110001 data readout planned in Q4 2024),Brazil: Universidade Federal de São Paulo (ARVO 2024), andMexico: Instituto de Oftalmología FAP (ARVO 2024).About Bascom Palmer Eye Institute

Bascom Palmer Eye Institute serves as the Department of Ophthalmology for the University of Miami Miller School of Medicine. The mission of BPEI is to enhance the quality of life by improving sight, preventing blindness, and advancing ophthalmic knowledge through compassionate patient care and innovative research. For 2023-2024, U.S. News & World Report (“U.S. News”) ranked BPEI as the nation’s best in ophthalmology, marking the 22nd time and 20th consecutive year that BPEI has received the No. 1 ranking since U.S. News began surveying American physicians for its annual “Best Hospitals” rankings 34 years ago.

About Provectus

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus’s lead HX molecule is named rose bengal sodium.

Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.

Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at https://www.provectusbio.com.

FORWARD-LOOKING STATEMENTS: The information provided in this press release may include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Such statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.

The safety and efficacy of Provectus’s drug agents and/or their uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any revenue levels.

Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and the Company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.

Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission, including those described in Item 1A of:

The Company’s Annual Report on Form 10-K for the period ended December 31, 2023.

#####

Contact:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999

@kiddlesnmore2
3 weeks ago
1) Powdered eggs
2) Powdered milk
3) Powdered whey protein
4) Powdered soups
5) Powdered Cheese
6) Powdered peanut butter
7) Powdered fruits
8) Powdered vegetables

Bascon Palmer has 4 papers related to PV-10 at the ARVO conference this week

Corneal epithelium
B0448: Evaluating the Safety of Rose Bengal Photodynamic Therapy 227
Jordan Huang, Esdras A. Arrieta, Andrea Naranjo, Pedro Monsalve, Keenan Mintz, Jeffrey C. Peterson, Alejandro Arboleda, Heather Ann Durkee, Mariela C. Aguilar, Sander R. Dubovy, Darlene Miller, Roger Leblanc, Guillermo Amescua, Jean-Marie A. Parel, Jaime D. Martinez-Martinez

Keratitis
B0580: Title: Enhanced Fungal Inhibition with High-Dose Rose Bengal Photodynamic Antimiocrobial Therapy 372
Salomon Merikansky, Heather Ann Durkee, Juan Carlos Navia, Felipe Echeverri Tribin, Katherine Krishna, Anam Ahmed, Alex Gonzalez, Cornelis Rowaan, Harry W. Flynn, Jean-Marie A. Parel, Darlene Miller, Guillermo Amescua

Keratitis
Inhibition of Fungal Isolates via Singlet Oxygen Generation from Erythrosin B and Rose Bengal Photodynamic Antimicrobial Therapy 432
Anam Ahmed, Braulio Carrera Loureiro B Ferreira, Heather Ann Durkee, Lillian Aston, Leonardo Gonzalez, Jessica Mar, Jeffrey C. Peterson, Katherine Krishna, Brandon Chou, Marco Ruggeri, Fabrice Manns, Harry W. Flynn, Guillermo Amescua, Darlene Miller, Roger Leblanc, Jean-Marie A. Parel

Pathobiology of microbial infections
B0010: Exploring the Combination of Rose Bengal Photodynamic Antimicrobial Therapy and Existing Antifungals 503
Katherine Krishna, Brandon Chou, Heather Ann Durkee, Felipe Echeverri Tribin, Anam Ahmed, Jessica Mar, Braulio Carrera Loureiro B Ferreira, James Lai, Roger Leblanc, Harry W. Flynn, Guillermo Amescua, Darlene Miller, Jean-Marie A. Parel

NEWS -- Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)

KNOXVILLE, TN, May 02, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office has allowed patent application 17/232,393, titled “Halogenated Xanthene Composition and Method for Treating Hematologic Cancers” (formerly “Composition and Method for Oral Treatment of Leukemia”). The application covers the use of Provectus’s pharmaceutical grade rose bengal sodium (“RBS”) active pharmaceutical ingredient for the single agent or combination therapy treatment of pediatric and adult leukemias. Earlier this year, Provectus announced notices of allowance and award for U.S. patents of RBS in virology, pediatric solid tumor cancers, and vaccines.

Innovate Calgary, the innovation company of the University of Calgary in Alberta, Canada, is a co-assignee and Aru Narendran, MD, PhD, Professor of Pediatrics, Oncology, Biochemistry and Molecular Biology and Physiology and Pharmacology at the University’s Cumming School of Medicine is a co-inventor on all four patent awards.

Dominic Rodrigues, President and Vice Chairman of Provectus’s Board of Directors said, “As we remain focused on advancing intratumoral administered cancer immunotherapy PV-10 towards initial drug approval for metastatic pancreatic cancer, our evidence-based confidence in the potential and possibilities of oral administration of rose bengal sodium for the treatment of disease continues to grow.”

About Provectus

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus’s lead HX molecule is named rose bengal sodium.

Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.

Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, https://ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at https://www.provectusbio.com.

FORWARD-LOOKING STATEMENTS: The information in this press release may include “forward-looking statements,” within the meaning of U.S. securities legislation, relating to the business of Provectus and its affiliates, which are based on the opinions and estimates of Company management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “project,” “predict,” “potential,” “targeting,” “intend,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.

Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.

Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission (SEC), including those described in Item 1A of:

The Company’s Annual Report on Form 10-K for the period ended December 31, 2023.

#####

Contact:

Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999

It’s the same as before except no stock price posted.

I know several who where there that are no longer sure what exists there (IV) as you can no longer see anything but a sign in page. Not going to join something I dont even know what it is anymore... Are you a member there? Has it changed? what is going on there? How the heck are they supposed to get new members when no one knows what they are getting?

interesting substack post for PV

Intralesional Path to Cancer Drug Approval
Fill Factor: the ratio of PV-10 volume to tumor volume to deliver a constant dose of rose bengal sodium per quantity of tumor

IV is subscription based service only now.

Do you need to pay 10 dollars a month to get back on IV now or is it still like it was?

https://open.substack.com/pub/provectus/p/intralesional-path-to-cancer-drug?r=h1cx0&utm_medium=ios

Excellent

Blue got right back to me and I now have access restored! I'm much impressed, to say the least...

So I'll see everybody going forward on InvestorVillage!

Ralph "Blue" Kidd
Chief Customer Liaison blue@investorvillage.com
504-250-0021

Unfortunately I don't have Blue's email address or other means of making contact since I can't log-in on the site! You got an email address for Blue that you can provide me? Quite frustrating, I must say...

I'm gonna try using Blue@InvestorVillage.com to see if that works...

Send Blue a message

It won't let me sign in using my long time password on my Mac when I use either Safari or Brave browsers. It did allow me to sign in the last time the site was up for a day or two, more than a week ago...

I was able to sign in on my computer and iPhone.

I have been able to sign on using my old password on a Win 10 desktop using the Brave browser. Can not sign on with my Android phone, have not tried my Android tablet.

It looks like IVillage is online again but won't allow sign in with old passwords, anybody have any insight/opinion on what to do to best protect ourselves in this situation? Has anyone gotten any correspondence from them about the situation?

I agree, the current SP is down right silly, and when this takes off it will be amazing for all long term suffering investors lol

When you read thru the last two posts on this board and the latest Provectus Substack posting, you can not help being impressed with the potential of this company. Combine that with the `shareholder value' theme that Dom and Ed constantly align themselves with, I just can not see why we are trading for a couple dimes per share. Collaborations with Moffet Cancer, Univ of Miami/Bascom Palmer, Univ of Calgary, Univ of TN, HD Anderson and others sure think we are worth their time and effort. It feel like something will break in our favor soon. Yes much of this is all pre-trial, but progress is being made.

Identification and In Vivo Validation of Unique Anti-Oncogenic Mechanisms Involving Protein Kinase Signaling and Autophagy Mediated by the Investigational Agent PV-10

Simple Summary
Novel therapeutics are urgently needed for high-risk and refractory solid tumors. Clinical studies have demonstrated the safety and efficacy of PV-10 (10% rose bengal sodium) by intralesional injection in skin cancer. However, this agent has not yet been evaluated for the treatment of various adult solid tumors. The aim of our study was to test PV-10 in breast, colorectal, head and neck, and testicular cancers. Using a combination of in vitro and in vivo experiments, we found that PV-10 exhibits anti-cancer activity against a panel of human cell lines derived from these tumors. Our results support further clinical development of PV-10 for the treatment of solid tumors in adults.

link to webpage with paper

NEWS -- Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers

Research on breast, colorectal, head and neck, and testicular cancers

Novel downregulation of WNK1 and Wnt signaling[/listKNOXVILLE, TN, April 18, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from preclinical research by the University of Calgary on oral administration of Provectus’s pharmaceutical-grade rose bengal for the treatments of solid tumor cancers were published in the open access journal of oncology Cancers.

Titled Identification and In Vivo Validation of Unique Anti-Oncogenic Mechanisms Involving Protein Kinase Signaling and Autophagy Mediated by the Investigational Agent PV-10, a copy of the University of Calgary’s journal article is available here: https://www.mdpi.com/2072-6694/16/8/1520.

This work has been part of research conducted by Aru Narendran, M.D., Ph.D., professor in the departments of Pediatrics, Oncology, and Biochemistry & Molecular Biology, and members of the Narendran Lab at the University of Calgary’s Cumming School of Medicine in Calgary, Alberta, Canada.

The Narendran Lab provided preclinical proof-of-concept data supporting the efficacy of Provectus’s rose bengal in a panel of adult solid tumors. The Lab identified that the Company’s rose bengal downregulated WNK1 and Wnt signaling. In mice, the Narendran Lab also confirmed the clinical utility of Provectus’s rose bengal by intratumoral (aka intralesional) administration and demonstrated potential utility by oral administration.

Dominic Rodrigues, the Company’s President and Vice Chairman of its Board of Directors stated, “Provectus is focused on initiating an FDA-cleared, lead clinical development program for intratumoral cancer immunotherapy PV-10 to treat hepatic metastatic pancreatic cancer, and pursuing a path to an initial drug approval for PV-10. The Company previously demonstrated its systemic response and systemic immune signaling and activation in clinical settings for metastatic liver cancers.”

Mr. Rodrigues added, “Building on PV-10’s clinical safety, efficacy, and immunotherapeutic profile, the Narendran Lab’s preclinical data suggest that Provectus’s pharmaceutical-grade rose bengal delivered by oral administration may have the potential to treat a larger pool of solid tumor cancers.”

About Provectus

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus’s lead HX molecule is named rose bengal sodium.

Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.

Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, https://ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at https://www.provectusbio.com.

FORWARD-LOOKING STATEMENTS: The information provided in this press release may include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Such statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.

The safety and efficacy of Provectus’s drug agents and/or their uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any revenue levels.

Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and the Company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.

Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission, including those described in Item 1A of:

The Company’s Annual Report on Form 10-K for the period ended December 31, 2023.

#####

Contact:

Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999

LTG, sure hope you're right about a rocket to da moon soon. And glad to see some IVillagers posting here, let's use this site until IV can recover their site and once again provide a safe posting place for us. I'm not a facebooker but my wife is and asked to join that group, but we see no posts there today so we wonder how active it is anyway. Not that IVillage was all that active, outside of BM who I've generally kept on ignore the past few years!

My best to everybody in PVCT land!!